145 related articles for article (PubMed ID: 10555932)
1. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.
Linden P; Lee L; Walsh TJ
Pharmacotherapy; 1999 Nov; 19(11):1261-8. PubMed ID: 10555932
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
[TBL] [Abstract][Full Text] [Related]
4. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
5. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
6. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
Wiley JM; Seibel NL; Walsh TJ
Pediatr Infect Dis J; 2005 Feb; 24(2):167-74. PubMed ID: 15702047
[TBL] [Abstract][Full Text] [Related]
8. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
Slain D; Miller K; Khakoo R; Fisher M; Wierman T; Jozefczyk K
Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
Linden P; Williams P; Chan KM
Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of amphotericin B lipid complex.
Luke RG; Boyle JA
Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187
[TBL] [Abstract][Full Text] [Related]
13. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Fleming RV; Kantarjian HM; Husni R; Rolston K; Lim J; Raad I; Pierce S; Cortes J; Estey E
Leuk Lymphoma; 2001 Feb; 40(5-6):511-20. PubMed ID: 11426524
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
Herbrecht R; Auvrignon A; Andrès E; Guillemain R; Suc A; Eyer D; Pailler C; Letscher-Bru V; Leverger G; Schaison G
Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):77-82. PubMed ID: 11305476
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Walsh TJ; Hiemenz JW; Seibel NL; Perfect JR; Horwith G; Lee L; Silber JL; DiNubile MJ; Reboli A; Bow E; Lister J; Anaissie EJ
Clin Infect Dis; 1998 Jun; 26(6):1383-96. PubMed ID: 9636868
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
Drew RH; Dodds Ashley E; Benjamin DK; Duane Davis R; Palmer SM; Perfect JR
Transplantation; 2004 Jan; 77(2):232-7. PubMed ID: 14742987
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
Sharkey PK; Graybill JR; Johnson ES; Hausrath SG; Pollard RB; Kolokathis A; Mildvan D; Fan-Havard P; Eng RH; Patterson TF; Pottage JC; Simberkoff MS; Wolf J; Meyer RD; Gupta R; Lee LW; Gordon DS
Clin Infect Dis; 1996 Feb; 22(2):315-21. PubMed ID: 8838189
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex.
Rapp RP; Gubbins PO; Evans ME
Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
[TBL] [Abstract][Full Text] [Related]
19. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies.
Martino R; Subirá M; Sureda A; Sierra J
J Antimicrob Chemother; 1999 Oct; 44(4):569-72. PubMed ID: 10588324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
